Skip to content

A randomized controlled study for the efficacy of endoscopic radiofrequency ablation and anti-reflux mucosectomy in the treatment of gastroesophageal reflux disease

A randomized controlled study for the efficacy of endoscopic radiofrequency ablation and anti-reflux mucosectomy in the treatment of gastroesophageal reflux disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022307
Enrollment
Unknown
Registered
2019-04-04
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal reflux disease

Interventions

Group A:endoscopic radiofrequency ablation
Group B :endoscopic anti-reflux mucosectomy

Sponsors

Institute of Digestive Diseases, Southwest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-65 years, gender not limited; (2) The patients underwent gastroscopy for reflux, heartburn, and retrosternal pain, and was diagnosed as GERD according to the microscopic manifestations and pH monitoring; (3) Indications for endoscopic radiofrequency ablation and anti-reflux mucosectomy, including obvious reflux symptoms (lasting for more than three months), daily drug control, and 24-hour pH monitoring abnormalities (time percentage of pH 4%); (4) Complete and reliable clinical data; (5) The patients are willing to accept either endoscopic radiofrequency ablation or anti-reflux mucosectomy.

Exclusion criteria

Exclusion criteria: (1) Severe esophagitis (grade C and D in Los Angeles), history of esophageal and gastric surgery, esophageal columnar epithelium > 3cm, long-segment Barrett's esophagus, hiatal hernia > 2cm, stage 4 sleep apnea syndrome, combined sclerodermia and other systemic diseases related to abnormal esophageal motor function; (2) Serious chronic kidney injury, severe congestive heart failure and arrhythmia, drug-uncontrolled hypertension, cardiogenic chest pain, combined with achalasia and other diseases causing reflux; (3) Duration of pregnancy or lactation; (4) Of severe mental behavior abnormalities and other radiofrequency ablation or anti-reflux mucosal resection contraindications.

Design outcomes

Primary

MeasureTime frame
Gastroesophageal reflux disease self-testing scale(GerdQ);

Secondary

MeasureTime frame
Degree of cardiac relaxation under gastroscope;Proton pump inhibitor usage;

Countries

China

Contacts

Public ContactQing Ji
1013364419@qq.com+86 13500380255

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026